PPT-SMV 150 mg QD SOF 400 mg QD
Author : alida-meadow | Published Date : 2018-02-17
Randomisation 1 1 1870 years HCV genotype 1 Naïve or pretreated with IFNbased regimen No cirrhosis HCV RNA 10000 IU ml No prior therapy with PI No HBV or HIV
Presentation Embed Code
Download Presentation
Download Presentation The PPT/PDF document "SMV 150 mg QD SOF 400 mg QD" is the property of its rightful owner. Permission is granted to download and print the materials on this website for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.
SMV 150 mg QD SOF 400 mg QD: Transcript
Randomisation 1 1 1870 years HCV genotype 1 Naïve or pretreated with IFNbased regimen No cirrhosis HCV RNA 10000 IU ml No prior therapy with PI No HBV or HIV coinfection OPTIMIST1 Study SMV SOF for genotype 1. Simmer the tripe for at least four to five hours in a stock pot of water. Tripe is a notoriously tough offal, the longer you simmer it, the more tender it becomes. // // VEAL SWEETBREADS 400/100 mg . qd. N = 120. N = 120. W12. SOF + RBV. > . 18 years. Chronic HCV infection. Genotype . 2. Naïve . or pre-treatment. with IFN-based regimen. Compensated cirrhosis allowed**. No HBV or HIV co-infection. 400/100 mg . qd. N = 500. N = 100. W12. Placebo. >. 18 years. Chronic HCV infection. Genotype 1, 2, 4, 5 or 6. Naïve or pre-treatment. with IFN-based regimen. Compensated cirrhosis allowed**. No HBV or HIV co-infection. OxidationstateNeutralOxidationstateElectronFormalElectronFormalCarbonyl(MCO)Halogen(MX)1Phosphine(MPRAlkyl(MR)Amine(MNRAryl(MAr)Amide(MNR1acyl(M 400/100/100 mg QD. N = 501. N = 440. W8. SOF/VEL 400/100 mg QD. >. 18 years. Chronic HCV infection. Genotype 1, 2, 3, 4, 5 or 6. Treatment-naïve or . IFN-experienced. Compensated cirrhosis **. allowed . qd. + SOF 400 mg . qd. N = 40. W12. 18-70 years. Chronic HCV infection. Genotype 4. HCV RNA > 10 000 IU/ml. Naïve or pre-treatment. with PEG-IFN + RBV. Compensated cirrhosis allowed. No HBV or HIV co-infection. N = 69. >. 18 years. Failure to SOF/VEL . or SOF/VEL + VOX . (LEPTON study). Any genotype. Compensated cirrhosis allowed. No HBV or HIV co-infection. Open-label. SOF/VEL: 400/100 mg FDC QD ; RBV: weight based in twice daily dose . qd. Non-randomised. Open-label. N =. 21. W12. SVR. 12. NIAID . SYNERGY GT4. Kohli. A. Lancet Infect Dis. 2015 Sep;15(9):1049-54. ≥ 18 years. Chronic HCV Genotype 4. Treatment-naïve or experienced. SOF + SMV + RBV. SOF + SMV. Randomisation. 2 : 1 : 2 : 1*. Open-label. * . Randomisation. was stratified on genotype (1a or 1b) in both cohorts, . IL28B . in cohort 1 and treatment history (naïve or non-responder) in cohort . SOF + RBV. Randomisation*. 1 : 1 : 1. Open-label. BOSON . Study. : SOF + RBV . +. PEG-IFN . for genotypes 2 and 3. ≥ 18 years. Chronic HCV infection. Genotype 2, treatment-experienced with cirrhosis. 400/100/100 mg QD. N = 263. N = 152. W12. Placebo. >. 18 years. Chronic HCV infection. Genotype 1, 2, 3, 4, 5 or 6. NS5A inhibitor-experienced . for ≥ 4 weeks (exclusion if . discontinued due to an adverse. Arie Gurfinkel (SEI/CMU). based on material by Prof. Clarke and others. Brief Review. 2/18/2005. 3. Symbolic Model . Verifier (SMV). Ken McMillan, . Symbolic Model Checking: An Approach to the State Explosion Problem. ≥ 18 years. Chronic HCV infection. Genotype 1 or 4. HCV RNA > 10 000 IU/ml. Treatment-naïve or pre-treated. w. ith PEG-IFN ± RBV. Cirrhosis (> 14.5 . kPa. on . FibroScan. ). Portal hypertension or liver . Int J Anat Var Vol 12 No 1 March 201924 Department of Bio-Medical Sciences, Philadelphia College of Osteopathic Medicine, Philadelphia-PA 19131, USACorrespondence: Dr. Mei Xu, Department of Bio-Medica
Download Document
Here is the link to download the presentation.
"SMV 150 mg QD SOF 400 mg QD"The content belongs to its owner. You may download and print it for personal use, without modification, and keep all copyright notices. By downloading, you agree to these terms.
Related Documents